Patients were randomized to treatment with CoQ10 capsules (COQ10 Softgel capsule 60 mg each Solgar, Inc. The study was approved by our institutional Helsinki committee. history of myopathy or myalgia prior to initiation of Statin treatment), clinical evidence of hepatic dysfunction (ALT or AST above X2 of upper normal limit or elevated bilirubin, alkaline phosphatase above local laboratory limits), renal dysfunction (estimated glomerular filtration rate below 60 ml/min/1.73m2), or overt endocrine disease coagulopathy, active malignancy or other serious medical conditions, and self-administration of CoQ10 prior to enrolment.Įach patient gave a written informed consent before participating in the study. Those who reported diminish symptoms while off statin, and recurrence of myalgia while back on a statin, were included in the study.Įxclusion criteria were: myopathy unrelated to statin therapy (e.g. Patients with statin induced myalgia were included: patients who were treated with a statin and complained of myalgia were asked to stop taking the statin for 2-3 weeks and then start taking it again. Prior to recruitment each patient was evaluated for clinical or laboratory evidence of hepatic, renal or endocrine disease, coagulopathy, or other serious medical conditions. Patients were recruited from cardiology clinics. The study was a randomized double-blind, placebo-controlled study. The present study was designed to evaluate whether CoQ10 supplementation would reduce myalgic symptoms in patients with statin-induced myalgia. This fact plus the role of CoQ10 in mitochondrial energy production and the importance of mitochondria in muscle function has prompted the hypothesis that statin-induced CoQ10 deficiency contributes to in statin-associated myopathy. Statins have been shown to reduce serum levels of CoQ10 16% to 38% 6, 7, 8, 9, 10, 11. Statins block production of farnesyl pyrophosphate, an intermediate in the production of CoQ10. CoQ10 is a naturally occurring, fat-soluble quinone participating in electron transport during oxidative phosphorylation in mitochondria, which protects against oxidative stress produced by free radicals 3, and regenerates active forms of the antioxidants ascorbic acid and tocopherol (vitamin E) 4, 5. Although generally safe, their most serious and frequent side effects are myopathic complaints 1, 2. Statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors are the most effective medications for reducing low-density lipoprotein cholesterol concentrations, and cardiovascular morbidity and mortality.
0 Comments
Leave a Reply. |